Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the signaling mechanism underlying PTEN-mediated antitumor effect remains largely unknown, and the crosstalk between PTEN and CXCR4 in OS has not been investigated.
|
31571016 |
2020 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings provide the basis for establishing CXCR4 antagonist and PD-1/PD-L1 inhibitors co-administration as a novel therapeutic regimen for patients with osteosarcoma and hold great promise for improving the therapeutic effect of osteosarcoma.
|
31437795 |
2019 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By Real-time PCR and immunoistochemistry we found that high levels of CXCR4 gene and protein expression significantly correlated with OS progression, emphasizing the role of CXCR4/CXCL12 axis in tumour prognosis.
|
31193811 |
2019 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of Urothelial Carcinoma-Associated 1 Suppressed Cell Growth and Migration Through Regulating miR-301a and CXCR4 in Osteosarcoma MHCC97 Cells.
|
29523218 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicated that CXCR4 mediated osteosarcoma cell growth and lung metastases and this effect can be suppressed by miR-613 through directly downregulating CXCR4.
|
29845707 |
2018 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression and activation of NF-κβ Signaling relevant protein were analyzed to investigate the relationship between Akt and NF-κβ signaling after the down-regulation of CXCR4 in osteosarcoma cells.
|
29734183 |
2018 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of SDF-1 and CXCR4 in five OS cell lines was analyzed by qRT-PCR, western blotting and ELISA assays.
|
28038429 |
2017 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the relationship between CXCR7 and CXCR4 in osteosarcoma invasion induced by bone marrow microenvironment.
|
28468584 |
2017 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using tumor tissue microarrays, we analyzed the expression of CXCR4 and MMP9 among 34 primary osteosarcomas with pulmonary metastasis and 62 primary osteosarcomas without metastasis.
|
26546437 |
2016 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Higher CXCR4 mRNA levels were detected in the osteosarcoma cell lines compared to BMSCs.
|
25890096 |
2015 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We used western blotting and flow cytometry to detect CXCR4 and CXCR7 expression in two OS cell lines (LM8 and Dunn).
|
25997540 |
2015 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results showed that the expression of CXCR4 and β-catenin mRNA and protein was significantly higher in OS tissues compared to the surrounding non-neoplastic tissues.
|
26026718 |
2015 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study provides further evidence of the contributions of hypoxia and the HIF-1α/CXCR4 pathway to the progression of osteosarcoma, and suggests that this axis might be efficiently leveraged in the development of novel osteosarcoma therapeutics.
|
25444927 |
2015 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We performed immunohistochemistry, immunocytochemistry, quantitative real-time PCR, Western blots and fluorescent reporter assays to evaluate the correlation between CXCR4 and HIF-1α expression in human osteosarcoma specimens or SOSP-9607 cells under normoxic and hypoxic conditions.
|
24618817 |
2014 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, expression of the CXCL12 scavenging receptor CXCR7 in the CXCR4-expressing human 143B osteosarcoma cell line enhances its metastatic activity in intratibial primary tumors in SCID mice that predominantly metastasize to the lung and thereby closely mimic the human disease.
|
24040160 |
2013 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, some early genetic events such as the loss of RANKL and the gain of CXCR4 expressions probably facilitate the metastatic progression concomitant with the primary tumor establishment, supporting the role of the CXCR4 receptor in directing osteosarcoma metastases to the lung.
|
23845465 |
2013 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
In conclusion, YY1 and VEGF/CXCR4 seem to intervene in the pathogenesis of the malignant phenotype of osteosarcoma by acting on cell invasiveness and metastasis growth.
|
18339860 |
2008 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, YY1 and VEGF/CXCR4 seem to intervene in the pathogenesis of the malignant phenotype of osteosarcoma by acting on cell invasiveness and metastasis growth.
|
18339860 |
2008 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Transfection experiments with CXCR1 cDNAs corresponding to the CXCR1-Ha and the alternative CXCR1-HA haplotype showed reduced expression of CD4 and CXCR4 in CXCR1-Ha cells in human osteosarcoma cells as well as in Jurkat and CEM human T lymphocytes.
|
17360650 |
2007 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
These data show a possible explanation for the preferential osteosarcoma metastatic development into the lung, where SDF-1 concentration is high, and suggest that molecular strategies aimed at inhibiting the CXCR4/SDF-1 pathway, such as small-molecule inhibitors or anti-CXCR4 antibodies, might prevent the dissemination of osteosarcoma cells.
|
15701832 |
2005 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the high-grade osteosarcoma patient samples (n = 47), CXCR4 was the most commonly expressed (63%) and its expression level was inversely correlated to overall survival (P < 0.0001), event-free survival (P < 0.001), and metastasis-free survival (MFS; P = 0.002).
|
15814634 |
2005 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
In the high-grade osteosarcoma patient samples (n = 47), CXCR4 was the most commonly expressed (63%) and its expression level was inversely correlated to overall survival (P < 0.0001), event-free survival (P < 0.001), and metastasis-free survival (MFS; P = 0.002).
|
15814634 |
2005 |